Abstract
Purpose :
To assess the viability and quality of treatment of non-proliferative Diabetic Retinopathy with Ranibizumab and Aflibercept plus fenofibrate.
Methods :
Following, for a one-year period, 40 eyes in 20 diabetic patients, with elevated triglycerides and non-proliferative diabetic retinopathy. We divided the patients in 2 groups: Treatment and Control. In the treatment regimen, for the same patient, we used Ranibizumab in one eye and Aflibercept in the other one plus systemic fenofibrate 100mg/day for 3 months.
In the Control group, 10 patients (20 eyes) were treated with anti-VEGF (Ranibizumab and Aflibercept in each eye) alone.
Results :
In the treatment group, the control of diabetic retinopathy in the one-year period showed similar results between different anti-VEGF in the eyes, consistent with findings of other studies analyzing anti-VEGF alone.
In the control group, in which fenofibrates were not added to the treatment regimen, there was no difference in the disease progression control.
Conclusions :
Both Ranibizumab as Aflibercept has showed satisfactory answers in the treatment, and no differences was found in the results between them.
The fenofibrate was good to control elevated systemic triglycerides, but showed no improvement in diabetic retinopathy control.
Both Aflibercept and Ranibizumab are good options to treat the non-proliferative Diabetic Retinopathy, but associating triglycerides control medication showed no difference.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.